3-Methylguanine (3MeG) is a modified guanine base found in DNA. It is formed by the methylation of guanine at the N3 position. 3MeG can be generated by endogenous sources, such as the enzyme S-adenosylmethionine decarboxylase, or by exogenous sources, such as alkylating agents used in chemotherapy. 3MeG can induce mutations and has been implicated in the development of cancer. It is also a substrate for DNA repair enzymes, such as the methylguanine methyltransferase (MGMT) pathway. 3MeG is studied to understand its role in DNA damage and repair, its potential as a biomarker for cancer, and its possible use in developing new therapeutic strategies.'
3-methylguanine : A methylguanine carrying the methyl substituent at position 3.
2-amino-3-methyl-3,9-dihydro-6H-purin-6-one : A 3-methylguanine that is 3,9-dihydro-6H-purin-6-one substituted by an amino group at position 2 and a methyl group at position 3.
2-imino-3-methyl-1,2,3,9-tetrahydro-6H-purin-6-one : A 3-methylguanine that is 1,2,3,9-tetrahydro-6H-purin-6-one substituted by an imino group at position 2 and a methyl group at position 3.
2-amino-3-methyl-3,7-dihydro-6H-purin-6-one : A 3-methylguanine that is 3,7-dihydro-6H-purin-6-one substituted by an amino group at position 2 and a methyl group at position 3.
ID Source | ID |
---|---|
PubMed CID | 76292 |
CHEBI ID | 46893 |
CHEBI ID | 27564 |
CHEBI ID | 46892 |
SCHEMBL ID | 48433 |
SCHEMBL ID | 10379715 |
MeSH ID | M0129925 |
Synonym |
---|
unii-feq5689emb |
nsc 62622 |
feq5689emb , |
guanine, 3-methyl- (van) |
6h-purin-6-one, 2-amino-3,7-dihydro-3-methyl- |
einecs 220-988-9 |
nsc-62622 |
n3-methylguanine |
nsc62622 |
guanine, 3-methyl- |
2958-98-7 |
C02230 |
2-amino-3,7-dihydro-3-methyl-6h-purin-6-one |
3-methylguanine |
2-imino-3-methyl-1,2,3,9-tetrahydro-6h-purin-6-one |
CHEBI:46893 |
CHEBI:27564 |
n(3)-methylguanine |
CHEBI:46892 |
2-amino-3-methyl-3,7-dihydro-6h-purin-6-one |
2-amino-3-methyl-3,9-dihydro-6h-purin-6-one |
2-amino-3-methyl-7h-purin-6-one |
3-meg |
AKOS006230273 |
FT-0648527 |
SCHEMBL48433 |
AKOS022636953 |
SCHEMBL10379715 |
2-amino-3-methyl-3,7-dihydro-6h-purin-6-one # |
XHBSBNYEHDQRCP-UHFFFAOYSA-N |
2-amino-3-methyl-6,7-dihydro-3h-purin-6-one |
DTXSID90183755 |
3-methyl-guanine (van) (8ci) |
7-dihydro-3-methyl-2-amino-3-6h-purin-6-one |
7-dihydro-3-methyl-2-amino-3-6h-purin-6-one (9ci) |
Q38133599 |
2-amino-3,9-dihydro-3-methyl-6h-purin-6-one |
6h-purin-6-one, 2-amino-3,9-dihydro-3-methyl- |
Excerpt | Reference | Relevance |
---|---|---|
" We show that Aag protects against the toxic and clastogenic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and mitomycin C (MMC), as measured by cell killing, sister chromatid exchange, and chromosome aberrations." | ( Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Allan, JM; Dreslin, AJ; Engelward, BP; Samson, LD; Tomasz, M; Wyatt, MD, 1998) | 0.3 |
Class | Description |
---|---|
3-methylguanine | A methylguanine carrying the methyl substituent at position 3. |
3-methylguanine | A methylguanine carrying the methyl substituent at position 3. |
3-methylguanine | A methylguanine carrying the methyl substituent at position 3. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (43.75) | 18.7374 |
1990's | 6 (37.50) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 1 (6.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.54) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |